Array BioPharma Inc

Array BioPharma Inc Stock Forecast & Price Prediction

Live Array BioPharma Inc Stock (ARRY) Price
$13.17

13

Ratings

  • Buy 6
  • Hold 7
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$13.17

P/E Ratio

36.26

Volume Traded Today

$4.4M

Dividend

Dividends not available for ARRY

52 Week High/low

26.64/12.52

Array BioPharma Inc Market Cap

$2.16B

🛑 Alert: These ten stocks could have higher potential than $ARRY 🛑

Before you buy ARRY you’ll want to see this list of ten stocks that have huge potential. Want to see if ARRY made the cut? Enter your email below

ARRY Summary

Based on ratings from 13 stock analysts, the Array BioPharma Inc stock price is expected to increase by 70.24% in 12 months. This is calculated by using the average 12-month stock price forecast for Array BioPharma Inc. The lowest target is $15.00 and the highest is $35.00. Please note analyst price targets are not guaranteed and could be missed completely.

ARRY Analyst Ratings

About 13 Wall Street analysts have assignedARRY 6 buy ratings, 7 hold ratings, and 0 sell ratings. This means that analysts expect Array BioPharma Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARRY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ARRY stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

vikram bagri
Citi

Hold

$16.5

maintained

Jan 31, 2024
dushyant ailani
Jefferies

Hold

$15.0

maintained

Jan 30, 2024
jordan levy
Truist Financial

Buy

$25.0

maintained

Jan 23, 2024
christine cho cfa
Barclays

Hold

$15.0

downgraded

Jan 22, 2024
michael blum
Wells Fargo

Hold

$19.0

downgraded

Jan 8, 2024
maheep mandloi
Mizuho Securities

Hold

$20.0

maintained

Jan 3, 2024
donovan schafer cfa
Northland Securities

Buy

$27.0

maintained

Jan 3, 2024
julien dumoulin smith
Bank of America Securities

Buy

$21.0

maintained

Dec 26, 2023
joseph osha
Guggenheim

Buy

$24.0

maintained

Dec 19, 2023
kashy harrison
Piper Sandler

Hold

$22.0

downgraded

Dec 19, 2023
mark strouse
J.P. Morgan

Buy

$35.0

maintained

Dec 15, 2023
sean milligan
Janney Montgomery

Buy

None

maintained

Dec 14, 2023
tristan richardson
Scotiabank

Buy

$33.0

maintained

Dec 11, 2023
andrew percoco
Morgan Stanley

Hold

$19.0

maintained

Dec 8, 2023
derek soderberg
Cantor Fitzgerald

Buy

$22.0

maintained

Nov 9, 2023
brian k. lee
Goldman Sachs

Buy

$31.0

reiterated

Nov 8, 2023
philip shen
Roth MKM

Buy

$30.0

maintained

Nov 8, 2023
jon windham
UBS

Buy

$33.0

maintained

Nov 8, 2023
thomas boyes
TD Cowen

Hold

$22.5

maintained

Nov 8, 2023
moses sutton
Exane BNP Paribas

Hold

$21.0

initiatedcoverage

Oct 20, 2023

ARRY Company Information

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.

ARRY
Array BioPharma Inc (ARRY)

When did it IPO

2020

Staff Count

1,058

Country

United States

Sector/Industry

Technology/Solar

CEO

Mr. Kevin G. Hostetler

Market Cap

$2.16B

Array BioPharma Inc (ARRY) Financial Data

In 2023, ARRY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARRY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $1.64B
  • Operating Margin TTM 11.5%
  • Gross profit TTM $227.3M
  • Return on assets TTM 7.6%
  • Return on equity TTM 22.6%
  • Profit Margin 6.7%
  • Book Value Per Share 1.84%
  • Market capitalisation $2.16B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $0.38
... ...

Similar Stocks to Array BioPharma Inc - ARRY

🛑 Alert: These ten stocks could have higher potential than $ARRY 🛑

Before you buy ARRY you’ll want to see this list of ten stocks that have huge potential. Want to see if ARRY made the cut? Enter your email below

...

ARRY Frequently asked questions

The highest forecasted price for ARRY is $35.00 from mark strouse at J.P. Morgan.

The lowest forecasted price for ARRY is $15.00 from christine cho cfa from Barclays

The ARRY analyst ratings consensus are 6 buy ratings, 7 hold ratings, and 0 sell ratings.